May 20, 2024 07:17 AM EDT
R&D

Gilead­'s rare liv­er dis­ease drug im­proves symp­toms in an­oth­er Phase 3 study ahead of FDA de­ci­sion

Katherine Lewin

News Reporter

Gilead re­port­ed more pos­i­tive da­ta over the week­end from its rare liv­er dis­ease drug can­di­date se­ladel­par, which it got when it

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­haven stock sinks on three-month de­lay for neu­ro drug's FDA ap­proval de­ci­sion

Ex­clu­sive: Drug com­pounder Em­pow­er was built on risky short­cuts, ex-em­ploy­ees and in­spec­tions al­lege

Up­dat­ed: Mer­ck KGaA con­tin­ues US tar­iff sur­charge but at a 'de­creased' rate 

Hen­grui, one of Chi­na's lead­ing biotechs, an­tic­i­pates $1.2B in pro­posed Hong Kong list­ing

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

Ex­clu­sive: 17 health sys­tems are work­ing with Abun­dant Ven­ture Part­ners to de­vel­op tech

A service from the Financial Times